Organigram Global Inc. (OGI:CA) Q2 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Organigram Global Inc. reported its second-quarter fiscal 2026 results on May 12, showing a 9 percent decline in net revenue to CAD 59.8 million. The Canadian cannabis leader still holds the top market share position, yet the quarter highlighted ongoing pressures in key product categories. The company responded by lifting its full-year revenue guidance to more than CAD 350 million, citing the recent acquisition of Sanity Group in Germany.
Revenue Decline Masks Operational Progress
Gross revenue reached CAD 93.3 million for the three months ended March 31, down from CAD 102.8 million a year earlier. Lower sales of vapes and infused pre-rolls drove most of the shortfall, while international revenue held steady at CAD 6.1 million. Adjusted gross margin narrowed to 31 percent of net revenue, reflecting both the revenue mix and higher provisions for returns.
Despite these headwinds, the company achieved a record quarterly harvest exceeding 32,000 kilograms, a 56 percent increase from the prior year. Average THC potency at its Moncton facility also reached new highs. These gains in cultivation efficiency point to improving fundamentals that management expects to support stronger results later in the fiscal year.
Acquisition Reshapes Outlook
Organigram completed the purchase of Sanity Group, Germany’s leading cannabis company, shortly after the quarter closed. The deal is projected to add roughly EUR 25 million in average quarterly revenue over the next twelve months. As a result, the company revised its fiscal 2026 net revenue target upward from more than CAD 300 million to more than CAD 350 million.
Adjusted EBITDA guidance remains above last year’s level, and free cash flow is now expected to reach break-even. Capital expenditures stay capped below CAD 10 million. The acquisition was funded in part by a CAD 60 million debt facility from ATB Financial, preserving liquidity for further European expansion.
Key Financial Metrics at a Glance
| Metric | Q2 2026 | Change vs. Prior Year |
|---|---|---|
| Net Revenue | CAD 59.8 million | -9% |
| Adjusted EBITDA | CAD 0.9 million | -82% |
| Net Income (Loss) | CAD (0.9) million | vs. CAD 42.5 million profit |
| Cash & Short-Term Investments | CAD 54.8 million | -35% |
Management Sees Stabilization Ahead
Chief Executive Officer James Yamanaka noted that operational adjustments and product enhancements are already stabilizing performance. He highlighted continued yield improvements and the upcoming contribution from Sanity Group as key drivers for the second half of the year.
Chief Financial Officer Greg Guyatt added that the cost structure continues to benefit from higher yields, automation investments, and prior efficiency measures. The company expects margin expansion and profitability gains to resume as revenue grows and international sales increase.
Positioning for European Growth
With the Sanity acquisition now complete, Organigram gains a scalable platform in one of Europe’s largest cannabis markets. The company also launched ten new vape and gummy products in Australia under its BOXHOT and Edison brands, now available in more than 4,000 pharmacies. Pending EU-GMP certification updates are expected to unlock additional export opportunities.
These moves position the company to diversify beyond its domestic base while addressing the competitive challenges that weighed on the first half of fiscal 2026. Investors will watch closely for evidence that the second-half recovery materializes as projected.